| Literature DB >> 32457087 |
Jaron van de Wardt1, A M Madelein van der Stouwe2,3, Michiel Dirkx4, Jan Willem J Elting5,3,6, Bart Post4, Marina Aj Tijssen5,3, Rick C Helmich4.
Abstract
Tremor is the most common movement disorder worldwide, but diagnosis is challenging. In 2018, the task force on tremor of the International Parkinson and Movement Disorder Society published a consensus statement that proposes a tremor classification along two independent axes: a clinical tremor syndrome and its underlying aetiology. In line with this statement, we here propose a stepwise diagnostic approach that leads to the correct clinical and aetiological classification of upper limb tremor. We also describe the typical clinical signs of each clinical tremor syndrome. A key feature of our algorithm is the distinction between isolated and combined tremor syndromes, in which tremor is accompanied by bradykinesia, cerebellar signs, dystonia, peripheral neuropathy or brainstem signs. This distinction subsequently informs the selection of appropriate diagnostic tests, such as neurophysiology, laboratory testing, structural and dopaminergic imaging and genetic testing. We highlight treatable metabolic causes of tremor, as well as drugs and toxins that can provoke tremor. The stepwise approach facilitates appropriate diagnostic testing and avoids unnecessary investigations. We expect that the approach offered in this article will reduce diagnostic uncertainty and increase the diagnostic yield in patients with tremor. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.Entities:
Keywords: dystonia; myoclonus; neurophysiol, clinical; parkinson's disease; tremor
Year: 2020 PMID: 32457087 PMCID: PMC7402459 DOI: 10.1136/jnnp-2019-322676
Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN: 0022-3050 Impact factor: 10.154
Figure 1Eight-step diagnostic approach to upper limb tremor. DT, dystonic tremor; EPT, enhanced physiological tremor; ET, essential tremor.
Figure 2Practical clinical algorithm. Isolated tremor syndromes are depicted in blue on the left side of the diagram, combined tremor syndromes in orange on the right side. Functional tremor is depicted in green on the right side. *For example, mildly unsteady tandem gait, questionably abnormal posturing of a body part, mild cognitive impairment, questionable bradykinesia or rigidity and other mild neurological signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. †For example, anxiety, fatigue, thyrotoxicosis, hypoglycaemia, pheochromocytoma, tremor-provoking medication (see table 1).
Overview of medication and toxins that may cause tremor52 53
| Medication | Toxins |
| Sympathomimetic drugs (adrenaline epinephrine, bronchodilators, theophylline) | Drugs of abuse (nicotine, alcohol and its withdrawal, cocaine, caffeine) |
| Antiarrhythmics (amiodarone) | Lead |
| Metoclopramide | Mercury |
| Antidepressants (SSRI, TCA) | Manganese |
| Lithium | Arsenic |
| Neuroleptics, tetrabenazine | Cyanide, DDT, CO |
| Antiepileptic drugs (valproic acid, carbamazepine, phenytoin) | Naphthalene |
| Immunosuppressants (tacrolimus, ciclosporin) | Toluene |
| Anticancer drugs (vincristine, cisplatin, paclitaxel, doxorubicin, cytosine arabinoside, ifosfamid, tacrolimus, 5-fluorouracil, methotrexate, tamoxifen, cytarabine) | Lindane |
| Hormones (thyroxine) | Solvents |
| Steroids (progesterone, anti-estrogens, adrenocorticosteroids) | Pesticides |
CO, carbon monoxide; DDT, dichlorodiphenyltrichloroethane; SSRI, selective serotonin reuptake inhibitor; TCA, tetracyclic antidepressants.
Treatable metabolic disorders that may evoke tremor57–59
| Metabolic disorder | Movement disorders | Laboratory tests | Gene |
|
| Dystonia, parkinsonism, ataxia, chorea, tremor | Serum ceruloplasmin, 24 hours urinary copper excretion | ATP7B |
|
| Ataxia, dystonia, | Oxysterols, chitotriosidase | NPC1, NPC2 |
|
| Dystonia, parkinsonism, chorea, | Plasma+urine organic acids, plasma acylcarnitines | GCDH |
|
| Ataxia, dystonia, | Plasma vitamin E level | TTPA |
|
| Dystonia, parkinsonism, tremor | CSF dopamine levels | GCH1 |
|
| Ataxia, dystonia, tremor, spasticity | Serum lactate, biochemical activities of respiratory chain complexes in skin or muscle, muscle CoQ10 level | Multiple genes |
CSF, cerebrospinal fluid; DRD, dopa-responsive dystonia.